Title:
MACROCYCLIC COMPOUND AS CDK INHIBITOR, PREPARATION METHOD THEREFOR, AND USE THEREOF IN MEDICINE
Document Type and Number:
WIPO Patent Application WO/2020/125513
Kind Code:
A1
Abstract:
The present invention relates to a macrocyclic compound as a CDK inhibitor, a preparation method therefor and the use thereof in medicine. Specifically, the present invention relates to a novel macrocyclic compound represented by a general formula (I), a preparation method therefor, a pharmaceutical composition containing the compound, the use thereof as a therapeutic agent, particularly as a CDK inhibitor, and the use thereof in treating cancers, inflammation, viral infections, cardiac hypertrophy or HIV, wherein each substituent of the general formula (I) is the same as that defined in the description.
Inventors:
DENG YONGQI (CN)
SUN JIAN (CN)
SUN JIAN (CN)
Application Number:
PCT/CN2019/124575
Publication Date:
June 25, 2020
Filing Date:
December 11, 2019
Export Citation:
Assignee:
CAMPHOR PHARMACEUTICALS LTD (CN)
International Classes:
C07D498/04; A61K31/519; A61P35/00
Domestic Patent References:
| WO2018177899A1 | 2018-10-04 | |||
| WO2015101293A1 | 2015-07-09 | |||
| WO2016015605A1 | 2016-02-04 | |||
| WO2016194831A1 | 2016-12-08 | |||
| WO2008079933A2 | 2008-07-03 |
Foreign References:
| CN101360751A | 2009-02-04 | |||
| CN102946732A | 2013-02-27 | |||
| CN107708719A | 2018-02-16 |
Other References:
MALLINSON, J.COLLINS, I.: "Macrocycles in new drug discovery", FUTURE MED. CHEM., vol. 4, 2012, pages 1409 - 1438, XP055071666, DOI: 10.4155/fmc.12.93
KWITKOWSKI VEPROWELL TMIBRAHIM A ET AL.: "FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma", ONCOLOGIST, vol. 15, no. 4, 2010, pages 428 - 435
MCDONALD EWORKMAN PJONES K: "Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer", CURR. TOP. MED. CHEM., vol. 6, no. 11, 2006, pages 1091 - 1107
HART SGOH KCNOVOTNY-DIERMAYR V ET AL.: "SB 1518, a novel macrocyclic pyrimidinebased JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies", LEUKEMIA, vol. 25, no. 11, 2011, pages 1751 - 1759, XP055163838, DOI: 10.1038/leu.2011.148
WILLIAM ADLEE ACHGOH KC ET AL.: "Discovery of kinase spectrum selective macrocycle", J. MED. CHEM., vol. 55, no. 1, 2012, pages 169 - 196, XP055071583, DOI: 10.1021/jm201112g
STUPP RVAN DEN BENT MJERRIDGE SC ET AL.: "Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC", J. CLIN. ONCOL., vol. 28, no. 15s, 2010, pages TPS152
HIRAI HTAKAHASHI-SUZIKI ISHIMOMURA T ET AL.: "Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo", INVEST. NEW DRUGS, vol. 29, no. 4, 2011, pages 534 - 543, XP019909526, DOI: 10.1007/s10637-009-9384-8
CHOU, T-CTALALAY P: "New Avenues in Developmental Cancer Chemotherapy", 1987, ACADEMIC PRESS, article "Applications of the median effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents", pages: 37 - 64
See also references of EP 3865488A4
KWITKOWSKI VEPROWELL TMIBRAHIM A ET AL.: "FDA approval summary: temsirolimus as treatment for advanced renal cell carcinoma", ONCOLOGIST, vol. 15, no. 4, 2010, pages 428 - 435
MCDONALD EWORKMAN PJONES K: "Inhibitors of the HSP90 molecular chaperone: attacking the master regulator in cancer", CURR. TOP. MED. CHEM., vol. 6, no. 11, 2006, pages 1091 - 1107
HART SGOH KCNOVOTNY-DIERMAYR V ET AL.: "SB 1518, a novel macrocyclic pyrimidinebased JAK2 inhibitor for the treatment of myeloid and lymphoid malignancies", LEUKEMIA, vol. 25, no. 11, 2011, pages 1751 - 1759, XP055163838, DOI: 10.1038/leu.2011.148
WILLIAM ADLEE ACHGOH KC ET AL.: "Discovery of kinase spectrum selective macrocycle", J. MED. CHEM., vol. 55, no. 1, 2012, pages 169 - 196, XP055071583, DOI: 10.1021/jm201112g
STUPP RVAN DEN BENT MJERRIDGE SC ET AL.: "Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC", J. CLIN. ONCOL., vol. 28, no. 15s, 2010, pages TPS152
HIRAI HTAKAHASHI-SUZIKI ISHIMOMURA T ET AL.: "Potent anti-tumor activity of a macrocycle-quinoxalinone class pan-Cdk inhibitor in vitro and in vivo", INVEST. NEW DRUGS, vol. 29, no. 4, 2011, pages 534 - 543, XP019909526, DOI: 10.1007/s10637-009-9384-8
CHOU, T-CTALALAY P: "New Avenues in Developmental Cancer Chemotherapy", 1987, ACADEMIC PRESS, article "Applications of the median effect principle for the assessment of low-dose risk of carcinogens and for the quantitation of synergism and antagonism of chemotherapeutic agents", pages: 37 - 64
See also references of EP 3865488A4
Attorney, Agent or Firm:
GE CHENG & CO., LTD. (CN)
Download PDF: